Celtic Biotech Ltd

About Celtic Biotech Ltd

Celtic Biotech is dedicated to developing innovative therapies for solid cancers and associated pain in humans. Their mission is to find curative treatments for cancer patients that do not compromise their quality of life, focusing on increasing survival rates, affordability, and quality of life through natural peptides derived from snake venom.

Products & Services

CB-24 (Crotoxin):A potent neurotoxin derived from snake venom that selectively targets and triggers programmed cell-death in cancerous cells while sparing healthy cells, primarily focused on treating solid tumors like non-small-cell lung cancer (NSCLC).

Specialties

Innovative cancer therapies Snake venom-derived peptides Solid tumor treatments Non-small-cell lung cancer (NSCLC) research

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 2720000 MR: - FA: €2.5m FAN: 2720000	D: 2023-07-18 FD: 2023-07-18	1 investors

Grant Latest

2023-07-18

$2.7M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

P

Paul Reid

CEO, Director and co-founder of Celtic Biotech

J

John Reid

COO, Director and co-founder of Celtic Biotech

D

Dorothy Bray

Director of Clinical Affairs

D

David Prestwich

Chief Finance Officer

F

François-Michel Delgado

Consultant physician/Medical Oncologist

Z

Zheng Hong Qin

Professor of Pharmacology

View 8 more team members with Pro

Unlock Full Team Directory

Recent News